Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Eubio Isoquercetin is a proprietary water-soluble formulation of **isoquercetin** developed by ALPS Pharmaceutical that is designed to improve the poor aqueous solubility and oral absorption of conventional isoquercetin. Isoquercetin is a naturally occurring flavonoid glycoside derived from *Sophora japonica* and has been studied as a small-molecule inhibitor of **protein disulfide isomerase**, a mechanism proposed to reduce thrombosis risk and potentially modulate thromboinflammatory pathways. The Eubio formulation uses all-natural food ingredients and reportedly achieves substantially higher quercetin exposure than ordinary isoquercetin without enzymatic modification, enabling lower doses versus standard isoquercetin preparations. The product appears to sit at the boundary between a drug-like nutraceutical and dietary supplement ingredient rather than a clearly approved pharmaceutical medicine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Eubio Isoquercetin.